Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Portage Biotech Inc PRTG

Healthcare Biotechnology
Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is engaged in advancing therapies to improve long-term treatment response, and quality of life in patients with cancers. The Company’s access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through... see more

Recent & Breaking News (NDAQ:PRTG)

Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer

GlobeNewswire February 27, 2023

Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit

GlobeNewswire February 15, 2023

Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022

GlobeNewswire November 29, 2022

Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GlobeNewswire November 10, 2022

Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck

GlobeNewswire November 8, 2022

Portage Biotech Provides Research and Development Update

GlobeNewswire September 14, 2022

Portage Biotech to Present at Upcoming Investor Conferences

GlobeNewswire September 8, 2022

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

GlobeNewswire August 29, 2022

Portage Biotech Announces Leadership Updates

GlobeNewswire August 18, 2022

UPDATE -- Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

GlobeNewswire August 1, 2022

Portage Biotech Announces Results for Fiscal Year Ended March 31, 2022

GlobeNewswire August 1, 2022

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

GlobeNewswire July 20, 2022

Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway

GlobeNewswire July 6, 2022

Portage Biotech Summarizes Data Presented at ASCO 2022 Annual Meeting Including Updates from Ongoing PORT-2 Study

GlobeNewswire June 6, 2022

Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity

GlobeNewswire April 25, 2022

Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting

GlobeNewswire April 13, 2022

Portage Biotech Provides Update on Clinical-Stage and Development Programs

GlobeNewswire March 31, 2022

Portage Biotech Announces Presentation of PORT-5 (STI-001) Late-Breaking Data at AACR 2022 Annual Meeting

GlobeNewswire March 9, 2022

Portage Biotech Announces Financial Results and Provides Business Update for Third Quarter of 2022 Fiscal Year

GlobeNewswire February 24, 2022

Portage Biotech Announces New Appointments to its Management Team and Board of Directors

GlobeNewswire February 15, 2022